Pharmaceutical Companies Sell One Product and Fund a Hundred Failures
The economics are a portfolio of lottery tickets financed by a small number of winners, running against a clock that starts before the drug is approved.
The Shape of the Business
A pharmaceutical company spends enormous sums on research where most projects fail. The small proportion that reach market can be extraordinarily profitable, because the marginal cost of manufacturing a pill is trivial relative to its price.
Gross margins on a successful branded drug are among the highest in any industry. The entire cost sits in the development that came before, and in the failures that never produced anything.
The company is therefore running a portfolio. Individual programme economics are irrelevant. What matters is whether the winners across the portfolio cover everything spent on the losers, plus a return.
The Attrition
| Stage | Purpose | Survival |
|---|---|---|
| Preclinical | Laboratory and animal work | Most compounds never advance |
| Phase I | Safety in small human groups | Majority proceed |
| Phase II | Does it work at all | The largest failure point |
| Phase III | Large scale efficacy and safety | Most survivors proceed |
| Regulatory review | Approval decision | Most filings succeed |
Phase II is where the money goes to die, because that is where a compound first has to demonstrate that it actually treats the condition in humans. The cost per programme rises steeply at each stage, so failures late in development are far more expensive than early ones.
The strategic priority is not raising the success rate. It is failing earlier, because a compound killed in Phase I costs a fraction of one killed in Phase III.
The Clock
A patent runs for a fixed term from filing, and filing happens early, long before the drug is approved. By the time a product reaches market, a substantial part of its protected life has already elapsed.
What remains is the window in which development costs must be recovered. When it closes, generic manufacturers enter, and for a small molecule drug the price collapses and the great majority of revenue disappears within a year or two.
This is the patent cliff, and it is unusual because the date is known years ahead. Every large pharmaceutical company has a public schedule of when its major revenue lines expire, which is why the sector acquires so persistently. Acquisition is how a company replaces revenue it knows it is about to lose.
Biologics Change the Picture
Biologic drugs, produced in living systems rather than synthesised chemically, are far harder to copy exactly. Competing versions are biosimilars rather than generics, requiring their own clinical work and manufacturing capability.
The result is that biologic revenue erodes more slowly and less completely after patent expiry than small molecule revenue does. That difference in the shape of the decline is a large part of why the industry shifted so heavily toward biologics.
Who Actually Pays
The list price of a drug is close to fiction in the United States market. Manufacturers pay rebates to pharmacy benefit managers and insurers, and the net realised price can be far below the headline figure.
This creates a system where the list price rises while the net price falls, and where the patient's out of pocket cost is often calculated on the list price they were never really charged. It is the source of most of the political argument about drug pricing, and it means headline price data is a poor guide to actual revenue.
The Research Has Moved
Much early stage innovation now happens in small biotechnology companies funded by venture capital, which are then acquired once a compound shows promise.
Large companies increasingly function as capital allocators, regulatory specialists, and global distribution networks rather than as primary discoverers. The acquisition price of a promising biotech is effectively the market's estimate of a probability weighted future revenue stream, which is why those valuations swing so violently on single trial results.
The Bottom Line
Pharmaceutical economics are a portfolio of high failure bets funded by a few very high margin successes, against patent clocks that are public and unforgiving. The strategic imperatives follow directly: fail early to save money, shift toward biologics because they erode more slowly, and acquire continuously to replace revenue with a known expiry date.